REVB Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Revelation Biosciences Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerREVB

Market Cap4.2M

Cash RunwayRunway 6-12 months

Next Catalystn/a

Public Research Snapshot

Revelation Biosciences Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Intravenous Gemini in Renal Insufficiency, Chronic | Chronic Kidney Disease stage3 | Chronic Kidney Disease stage4 (Phase 1 | Phase 2).

Pipeline

Asset	Indication	Modality	Stage	Public Note
Intravenous Gemini	Renal Insufficiency, Chronic \| Chronic Kidney Disease stage3 \| Chronic Kidney Disease stage4	n/a	Phase 1 \| Phase 2	Public pipeline row

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Runway 6-12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT06863467	Phase 1 \| Phase 2	COMPLETED	40	2025-07-22

Scientific Context

literature_publication | Unraveling MLL1-fusion leukemia: Epigenetic revelations from an iPS cell point mutation.
literature_publication | Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer.
literature_publication | Correction to: Neutralizing Antibody Sample Testing and Report Harmonization.
literature_publication | Revealing Comprehensive Food Functionalities and Mechanisms of Action through Machine Learning.
literature_publication | Neutralizing Antibody Sample Testing and Report Harmonization.

Want the full REVB research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.